To address this possibility, we measured a panel of relevant inflammatory cytokines that can be produced by anti-CTLA-4 and anti-PD-1 treatment and by adoptive transfer therapy of tumor-reactive lymphocytes. This evidence concerns the gene CTLA4 and neoplasm.